T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma.

By S. A. Ali, V. Shi, I. Maric, Michael L. Wang, D. Stroncek, J. Rose, Jennifer N. Brudno, M. Stetler-Stevenson, S. Feldman, B. Hansen and 4 more. Blood, 2016

722 citations recorded by the source corpus.

Subfields: Biomedical Engineering, Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/76e42ad3659965842af9443d1a6cd10d998f117b

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Biomedical Engineering

1. J. Kochenderfer
2. Jennifer N. Brudno

In Molecular Biology

1. C. June
2. Wendell A. Lim

In Oncology

1. J. Kochenderfer
2. Jennifer N. Brudno
3. C. June
4. Wendell A. Lim
5. S. Grupp
6. Michel Sadelain

Citations in the corpus

• Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management (2018, background): “Various electrolyte derangements can occur, including hyponatremia [8,11,21,22,29,30], hypokalemia [8,45], and hypophosphatemia [8,22,29,30,45].”
• The Principles of Engineering Immune Cells to Treat Cancer (2017, background): “gov NCT02546167) with CARs targeting B cell maturation antigen (BCMA, TNFRSF17, or CD269), multiplemyeloma patients have shown eradication of non-malignant plasma cells that also express BCMA, in addition to eradication of the myeloma cells (Ali et al., 2016).”
• B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma. (2019, background): “Responses were associated with significant but expected toxicities including cytokine release syndrome (CRS) and neurotoxicity (12), similar to those described with CD19-targeted CAR T cells in patients with B cell malignancies (13, 14).”
• T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma. (2018, methodology): “For all tested cytokines, P values and fold-difference for comparisons of cytokine levels with CRS grades are in the Data Supplement.”
• Tumor Antigen Escape from CAR T-cell Therapy. (2018, background): “Furthermore, loss of target antigen has also been observed in a patient with multiple myeloma treated with a CAR targeting BCMA (29) as well as in patients with glioblastoma multiforme who were treated with CARs targeting either EGFRvIII (30) or IL13Rα2 (31).”
• ASBMT Consensus Grading for Cytokine Release Syndrome and Neurological Toxicity Associated with Immune Effector Cells (2018, background): “CAR therapies targeting CD22 in B cell malignancies [5] and B cell maturation antigen (BCMA) in multiple myeloma [6] have been highly successful in early trials and are also forthcoming, along with combination approaches targeting multiple antigens simultaneously.”